Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 141Unknown 22Terminated 21Recruiting 20Active not recruiting 7Not yet recruiting 5Withdrawn 3Suspended 2No longer available 1

Sponsor Class

OTHER 2UNKNOWN 1

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 437Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 174Colorectal Neoplasms 156Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 130Lymphoma 127Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Brain Neoplasms 101Recurrence 100Head and Neck Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 96Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 74Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

nabiximols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Advanced Cancer × Clear all
NCT03122249 2024-05-08

OASIS

University of Iowa

Phase NA Withdrawn

Advanced Cancer

NCT05262842 2022-09-21

JS001+IMP4297 in Patients With Advanced Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn

Advanced Cancer

NCT02432612 2016-03-02

A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer

GWPharm

Phase 1 Withdrawn

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡